Introduction
Iron is an essential element in the body, forming the core of both haemoglobin and myoglobin. A healthy individual will have 4 -5 g iron in their body, and the 1 -2 mg lost per day is replenished by absorption from the duodenum. Iron levels are regulated, as iron can cause significant damage to cells through formation of peroxide radicals 1 .
This can result in life-threatening damage to the heart, liver, brain, pancreas and joints 2 .
Iron overload is caused by inherited disorders of metabolism or acquired from exogenous administration (e.g. iron administration or blood transfusion). The latter often occurs in the setting of haematological disorders with ineffective erythropoiesis.
Chronic kidney disease (CKD) is often associated with anaemia, due to deficient production of erythropoietin, and also reduced iron absorption and availability 3, 4 . This is partly due to increased production of hepcidin, the hormone that regulates iron absorption 5 . The treatment for anaemia consists of both parenteral iron supplements and erythropoiesis stimulating agents (ESA) [6] [7] [8] , although there is evidence of increased morbidity and mortality and many users become resistant to ESA 9 . Multiple infusions of iron are usually administered 10, 11 and these can result in overload. Whilst serum iron studies, including ferritin levels, have been used to monitor iron toxicity and guide replacement, ferritin can be affected by factors such as inflammation and infection 1 . We have recently shown that serum studies are inadequate for guiding iron status in subjects with CKD 12 . Furthermore, 60% of haemodialysis subjects have hepatic iron concentration (HIC) greater than twice normal 13 .
Secondary iron overload disorders are usually treated with iron chelation agents. While oral deferiprone 14 is available in Australia for patients with thalassaemia major who are unable to take desferrioxamine therapy or in whom desferrioxamine therapy has proven ineffective, deferasirox is the first oral iron-chelating drug approved by the Therapeutic Goods Administration for the reduction of chronic iron overload in patients with disorders of erythropoiesis. Although deferiprone has been available for several years, no pharmacokinetic data is available for patients on haemodialysis.
Deferasirox has a high, specific affinity for iron 15 , and is effective as a single daily dose.
In patients over 16 years old with -thalassaemia and transfusional iron overload, a dose of 20 mg/kg/day will maintain plasma levels within the therapeutic range of [15] [16] [17] [18] [19] [20] mol/l (trough) to 60-100 mol/l (peak) over 24 hours 16 . Deferasirox is metabolised through hepatic glucuronidation 17 , which can vary greatly from patient to patient. In many countries, regulatory authorities have approved the use of deferasirox in patients with creatinine clearance > 40 ml/min, simply because of the lack of safety and pharmacokinetic data. Moreover, the manufacturer's prescribing information warns against the use of deferasirox in patients with impaired renal function due to reported cases of acute renal failure.
There is a pressing need to evaluate efficacy and safety of potential therapies of iron overload complicating CKD. Access to accurate measurements of plasma deferasirox levels is limited 18, 19 . The aims of this study were to (1) develop and validate a simple method for the analysis of deferasirox in human plasma, and (2) conduct a phase 1 safety study of the administration of deferasirox at 10 mg/kg and 15 mg/kg daily in stable subjects undergoing haemodialysis for CKD, with monitoring of side effects and plasma deferasirox levels.
Methods

Study subjects and protocol
An open label, single arm, phase I pilot study to evaluate the pharmacokinetics and safety of deferasirox at 2 dose levels of 10 mg/kg/day and 15 mg/kg/day was conducted in 8 haemodialysis-dependent patients, who were receiving intravenous iron and erythropoietin therapy for treatment of anaemia of CKD. Power analysis determined that with n = 4, we had 90% power to detect a difference of 15 mol/l, where a = 0.05
and SD = 5, and 85% power to detect a difference of 35 mol/l, where SD = 15.
Subjects were included if they were able to provide written informed consent, aged 18-80 years, and fulfilled the following criteria: CKD dependent on haemodialysis for at Deferasirox and 13 C 6 -deferasirox standards were obtained from Novartis (North Ryde, Australia) and Alsachim (Illkirch-Graffenstaden, France) respectively. Due to low solubility in water, standards were first dissolved in methanol and subsequently diluted into 95% water/5% acetonitrile with 1% formic acid, representing the initial HPLC mobile phase composition. Both labelled and unlabelled standards were analysed over the concentration range 0.1 to 1000 ng/ml.
Sample preparation was adapted from the method of Chauzit et al. 19 . 100 l of plasma was combined with 100 l of internal standard solution and diluted 1:9 with dipotassium phosphate buffer (0.1 M, pH 3). This solution was vortexed for 5 seconds to convert the iron chelate back to free drug. Acetonitrile was added (300 ml) and The LC-MS/MS method was validated for the following parameters: selectivity, recovery, precision, linearity and sensitivity. Selectivity was determined by analysis of both spiked and drug-free plasma to determine the presence of any co-elution from matrix interference. Recovery was calculated by spiking deferasirox standard into plasma at the commencement and conclusion of sample preparation. Intra-day precision was determined by performing 5 replicate injections of deferasirox standard spiked into plasma (5, 50 and 500 ng/ml) and calculating a relative standard deviation (%RSD).
This was performed over three consecutive days to assess inter-day precision. Linearity was determined by plotting a standard curve of peak area versus drug concentration over the 0.1 to 500 ng/ml. Sensitivity was determined as a limit of detection with a signal-to-noise ration not less than 3:1 and a limit of quantification with a ration of not less than 10:1. 
Results
Deferasirox assay
Both deferasirox and 13 C 6 -deferasirox eluted from the column with a retention time of 8.9 minutes. Extraction of drug-free plasma showed no interference on any of the twelve MS/MS transitions used for labelled and unlabelled drug. Extraction recovery of deferasirox was 93%. Standard curves for both forms of the drug were linear over the range analysed (r 2 = 0.99 for both). The limit of detection for both forms of the drug was 0.1 ng/ml and the limit of quantification was 0.5 ng/ml. Overall the assay had an intra-day precision of 6.1% RSD, with the three concentrations having precision as follows: 5 ng/ml: 5.8%; 50 ng/ml: 9.2%; 500 ng/ml: 3.2%. The overall inter-day precision was 5.9% RSD, with the three concentrations as follows: 5 ng/ml: 4.3%; 50 ng/ml: 3.7%; 500 ng/ml: 9.8%.
Patient data
The baseline characteristics of the study subjects are summarised in Table 1, and there were no significant differences observed between the two patient groups for any of the parameters measured. Mean time on dialysis was substantially higher for patients receiving the 10 mg/kg dose (852 ± 128 days) than the 15 mg/kg dose (576 ± 234 days), although this was not statistically significant (p = 0.8).
There was no attrition, and all patients completed the full study. During the course of the study, there were no observed adverse clinical or biochemical test parameters on any of the study subjects at deferasirox doses of 10 mg/kg or 15 mg/kg daily ( Table 2 ).
Pharmacokinetic studies of deferasirox
Pharmacokinetic data is summarised in Table 3 
Discussion
This study has evaluated the pharmacokinetics and safety of deferasirox in 8 haemodialysis-dependent patients receiving intravenous iron for treatment of anaemia of CKD. It has also presented a new, simple and sensitive assay for deferasirox in plasma samples. Using this method, retention times were stable, justifying the use of 1% formic acid in the mobile phase, rather than a more complicated buffer. By taking advantage of the increased sensitivity of modern LC-MS systems, samples can be diluted prior to analysis, greatly reducing the potential for matrix interference.
Nisbet-Brown et al. 16 determined that for gap-free chelation coverage, plasma levels of deferasirox should be maintained between 15-20 (trough) and 60-100 mol/l (peak), and used a dose of 20 mg/kg to achieve this in adult patients with -thalassaemia. In this study, a dose of 10 mg/kg was insufficient to reach the suggested therapeutic concentrations with either acute or steady-state doses, although post-dialysis values for the steady-state doses were within this range. Doses of 15 mg/kg (both acute and steady-state) maintained levels within or above this range.
The primary aim of this study was to determine the pharmacokinetics of deferasirox in haemodialysis patients, not to determine its efficacy. Thus, we included patients who did not have a risk for iron overload as indicated by ferritin levels > 1000 g/l. With regards to the utility of ferritin in predicting start and stop rules for deferasirox treatment, this is primarily in secondary iron overload settings. We 12, 20 and others 21 have recently shown that elevated serum ferritin levels do not accurately predict or correlate with body iron stores in the general population or renal dialysis patients in 13 particular. Others 22, 23 have shown similar findings in secondary iron overload patients with low specificity for ferritin in assessing iron overload.
Plasma concentrations observed at a dose of 15 mg/kg, with either protocol, were much higher than previously observed in non-hemodialysis patients. Galanello et al. There are no data pertaining to the ability of deferasirox to be dialysed, however the compound binds to albumin (40 g/L) at 98-99% efficiency for deferasirox concentrations between 10 and 105 μg/mL 25 . Deferasirox and its metabolites are primarily excreted in the faeces (84% of the dose), and renal excretion of deferasirox and its metabolites is minimal (8% of the dose). Thus, it is not anticipated that haemodialysis would significantly affect the clearance of the drug.
Although pharmacokinetic data in patients without CKD would suggest minimal risk of accumulation of deferasirox owing to the minimal urinary excretion, the nearly 10-fold increase in AUC for deferasirox at a dose of 15 mg/kg compared to 10 mg/kg in our haemodialysis cohort suggests that uraemia may reduce faecal excretion or enhance intestinal reabsorption of deferasirox, thus resulting in higher than predicted plasma levels. In uremic rats, a decrease in intestinal protein membrane transporters such as Pglycoprotein (Pgp) and multidrug-resistance-related protein (MRP2) expression and function secondarily to serum uremic factors has been reported 26 . This reduction could explain the increased bioavailability of drugs such as deferasirox, which is known to be excreted via MRP2 17 , in renal failure. Deferasirox is also known to bind to 1-acid glycoprotein, but this binding decreases from 85% to 8% as deferasirox concentration increases from 0.5 to 105 g/ml 25 . Pharmacokinetic studies of other drugs that bind to 1-acid glycoprotein, such as ropivacaine 27 , have a greater AUC in uraemia, which may also have contributed to the increased bioavailability of deferasirox observed in this study.
This study has highlighted the need to profile drugs such as deferasirox in patients with chronic kidney disease and iron overload. The pharmacokinetics of deferasirox were different than expected in these patients, with a small dose increment from 10 to 15 mg/kg leading to a substantial increase in mean plasma concentration. While no adverse clinical parameters were observed in this study, it is clear that further research is needed to avoid potential adverse clinical outcomes and evaluate therapeutic efficacy for iron removal. 
